Clinical trials: Streptococcus Pneumoniae Vaccines
Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine.
- Trial name
- NCT00918580
- Testing
- 13-valent Pneumoccocal Conjugate Vaccine
- Where
- 19 sites in United States, Egypt and 5 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
Pneumococcal Infection
A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China
This study is primarily designed to evaluate the IgG immune responses to the 13 pneumococcal serotypes induced by 13vPnC compared with the immune responses induced by 7vPnC when measured 1 month after the infant series, and to…
- Trial name
- NCT01692886
- Testing
- 7-valent Pneumococcal Conjugate Vaccine, 13-valent Pnumococcal Conjugate vaccine
- Where
- 4 sites in China
- Volunteers
- 1,674 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
- Trial name
- NCT04642079
- Testing
- 20vPnC
- Where
- 43 sites in United States
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis A
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
This is a study to evaluate the immunogenicity and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a pneumococcal conjugate vaccine in children as young as 15 months of age.
- Trial name
- NCT00197002
- Testing
- GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™
- Where
- 18 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcus Pneumoniae
Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants
The purpose of the trial is to determine the minimum of doses of a new nine valent pneumococcal conjugate vaccine required to protect UK infants and toddlers
- Trial name
- NCT00197769
- Testing
- 9 valent pneumococcal con jugate vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Public Health England
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
This is a Phase 3, randomized, double-blind study with a 4-arm parallel design. Adults 18 through 49 years of age with no history of pneumococcal vaccination will be randomized in a 2:2:2:1 ratio to receive a single dose of…
- Trial name
- NCT03828617
- Testing
- 20vPnC, 13vPnC
- Where
- 21 sites in United States
- Volunteers
- 1,710 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccine
Impact of Vaccines on Antimicrobial Microbial Resistance
Vaccination is a potentially critical component of efforts to arrest development and dissemination of antimicrobial resistance (AMR), though little is known about vaccination impact within low-income and middle-income countries.
- Trial name
- IVAR (NCT06450379)
- Where
- Malawi
- Volunteers
- 13,200 people, healthy volunteers welcome
- Sponsor
- Malawi Liverpool Wellcome Programme
Pneumococcal Infections
13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent…
- Trial name
- NCT01432262
- Testing
- vaccine-13vPnC
- Where
- 4 sites in Mexico
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.
- Trial name
- NCT05667740
- Testing
- Gamma-PN3, Prevenar-13, Pneumovax-23
- Where
- Australia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
HIV
Pneumococcal Conjugate Vaccine (PCV) in HIV- Infected Children
The purpose of this study is to evaluate the immunogenicity and safety of 7 - valent pneumococcal conjugated vaccine in HIV - infected children, and assess the predictive factors for protective antibody responses after receiving…
- Trial name
- NCT01135082
- Testing
- valent pneumococcal conjugated vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Study is Open to Seniors Age 50 or Older
Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center
The overall goals of this program are to measure the impact of a pharmacist pneumococcal vaccine education program (PPVP) using a senior center model of care and provide the pneumococcal vaccine to eligible participants.
- Trial name
- PPVP (NCT01944462)
- Testing
- Pharmacist Pneumococcal Vaccine Program (PPVP)
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Meningococcal Meningitis, Measles
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00483574
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- Where
- 79 sites in United States, Chile
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diseases Caused by Streptococcus Pneumoniae Serotypes
Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)
The purpose of this study is to investigate and valuate the immunogenicity and safety of the 13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants and toddlers (the youngest could be 6 weeks…
- Trial name
- NCT02736240
- Testing
- 7-valent pneumococcal conjugate vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine
- Volunteers
- 2,760 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Pneumococcal Disease
Child Pneumococcal Serotype Epidemiology In Greece
Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide.
- Trial name
- NCT01111214
- Testing
- no intervention
- Where
- 9 sites in Greece
- Volunteers
- 457 people
- Sponsor
- Pfizer
Pneumonia, Pneumococcal, Vaccine
Pneumonia Vaccine Education Intervention Study
The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine.
- Trial name
- PVI (NCT06136832)
- Testing
- Pneumococcal Vaccine Education
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Geisinger Clinic
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in…
- Trial name
- NCT06524414
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
- Where
- 67 sites in United States, Puerto Rico
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.
- Trial name
- NCT00334334
- Testing
- Pneumococcal (vaccine)
- Where
- 66 sites in Germany, Poland and 1 more
- Volunteers
- 1,572 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
The aim of the current study is to determine whether ibuprofen, given as immediate or delayed prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune response in children receiving primary…
- Trial name
- NCT01235949
- Testing
- GSK1024850A (SynflorixTM), Infanrix hexa, Infanrix-IPV/Hib
- Where
- 23 sites in Romania
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who…
- Trial name
- NCT00624819
- Testing
- GSK1024805A, Prevenar, Infanrix hexa
- Where
- 6 sites in Poland
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malignancy, Cancer
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
This is a prospective interventional study designed to investigate the effect of Immune Reconstitution clinic visits and pneumococcal vaccination (PCV-21) on infection risk, anti-infective prophylaxis adherence, and vaccine…
- Conditions
- Malignancy, Cancer, Hematological Malignancies, Lymphoma
- Trial name
- NCT07071909
- Testing
- Commercial CAR-T, Investigational CAR-T
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center